Cytelabs launches DISH testing for Breast Cancer, Health News, ET HealthWorld

Bengaluru, 12 December 2023:Dual in situ hybridization (DISH) testing for breast cancer has been formally launched by Cytelabs, a first-of-its-kind, specialised oncopathology cancer diagnostic service powered by Cytecare Cancer Hospital. This is becoming a more and more common way to determine the HER2 status in breast cancer patients.Globally, DISH is revolutionising precise human epidermal growth factor receptor 2 (HER2) testing, which is essential for precision therapy in breast cancer. DISH was approved by the US Food and Drug Administration (USFDA). Patients and their families experience a significant reduction in anxiety and the waiting period (HER2 status report within 24-48 hours).Elaborating on the need to make this state-of-the-art technology easily accessible in India, Dr.Aparna Gangoli, Director, Cytelabs, said, “Cytelabs is the one-stop solution for tissue diagnosis of cancer and we understand the needs of oncologists as well as cancer patients. DISH promises quality results and short turnaround time ensuring that the treatment for breast cancer can be planned and initiated without wasting undue time.The prognostic and predictive implications of HER2 status makes accurate and efficient HER2 testing of paramount importance in characterizing all invasive breast carcinomas.”We first need to grasp certain fundamentals of breast cancer detection and treatment options in order to fully comprehend the significance of this development. HER2 positive and HER2 negative groups are used to make prognostic divisions for breast cancer cases. Targeted therapy with trastuzumab, a medication that obstructs the HER2 antigen sites on cancer cells expressing HER2, can be beneficial for patients who test positive for HER2.Determining the best course of treatment for patients requires accurate HER2 testing. Immunohistochemistry (IHC), which classifies cancer cells as HER2 positive, HER2 negative, or HER2 ambiguous, is the first line of inquiry for HER2 positive tumour cells. In order to determine the final HER2 status and enable the appropriate course of treatment to be initiated, the HER2 equivocal category requires additional testing using an advanced technology.“Traditionally, these equivocal cases are subjected to Fluorescent in situ hybridization (FISH) technique for the final status. This testmandatorily requires fluorescent microscope and trained personnel, which is not easily available in all Indian hospitals dealing with cancer cases. Hence this necessitates outsourcing this test to a specialized centre either within the city or outside,” explains Dr Gangoli.

Published On Dec 15, 2023 at 04:57 AM IST

Join the community of 2M+ industry professionals
Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

Get Realtime updates
Save your favourite articles

Scan to download App

Recommended For You